Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma.
Saved in:
| Title: | Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. |
|---|---|
| Authors: | Miller KC; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Johnson PC; Center for Lymphoma, Massachusetts General Hospital, Boston, MA, USA., Abramson JS; Center for Lymphoma, Massachusetts General Hospital, Boston, MA, USA.; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA., Soumerai JD; Center for Lymphoma, Massachusetts General Hospital, Boston, MA, USA., Yee AJ; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA., Branagan AR; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA., O'Donnell EK; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA., Saucier A; Tufts University School of Medicine, Boston, MA, USA., Jacobson CA; Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA., Frigault MJ; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA., Raje NS; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA. nraje@mgh.harvard.edu.; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA. nraje@mgh.harvard.edu. |
| Source: | Blood cancer journal [Blood Cancer J] 2022 Nov 01; Vol. 12 (10), pp. 146. Date of Electronic Publication: 2022 Nov 01. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
